The launch of Streamline for the B. Braun machines broadens our relationship and extends the value of our product portfolio to B. Braun’s Renal Therapies Division giving patients and providers greater access to NxStage’s high quality, value-added in-center offerings, said
We are pleased to broaden our relationship with NxStage by offering the unique Streamline technology to our dialysis customers, stated
NxStage’s latest generation blood tubing set is the Streamline. Streamline features an efficient and airless design intended to improve clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, treatment time, minimize heparin and waste, and optimize dose delivery, as measured in Kt/V. Streamline also includes NxStage’s patented LockSite® needleless access ports, which eliminate the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company’s Sharing Expertise® philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.
Consistently recognized by
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage’s Streamline blood tubing sets and other factors that are discussed in NxStage’s filings with the
VP, Investor Relations